Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies

Clinical trial NCT03317366 · NO_LONGER_AVAILABLE

Trial details

NCT number: NCT03317366
Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Status: NO_LONGER_AVAILABLE
Study type: EXPANDED_ACCESS

Proteus Syndrome PIK3CA-Related Overgrowth Spectrum (PROS)Growth Disorders

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.